Abstract
Gastric cancer (GC) has a high mortality rate with a poor 5-year survival. Helicobacter pylori (H. pylori) is present as part of the normal flora of stomach. It is found in the gastric mucosa of more than half of the world population. This bacterium is involved in developing H. pylori-induced GC due to the regulation of different micro ribonucleic acid (miRNA or miR). miRNAs are small noncoding RNAs and are recognized as prognostic biomarkers for GC that may control gene expression. miRNAs may function as tumor suppressors, or oncogenes. In this review, we evaluated studies that investigated the ectopic expression of miRNAs in the prognosis of H. pylori positive and negative GC.
Keywords: Gastric cancer, tissue mirna, Helicobacter pylori, normal flora, miRNA, gastric mucosa.
Current Pharmaceutical Design
Title:The Prognostic and Predictive Value of microRNAs in Patients with H. pylori-positive Gastric Cancer
Volume: 24 Issue: 39
Author(s): Seyed Mostafa Parizadeh, Reza Jafarzadeh-Esfehani, Amir Avan*, Maryam Ghandehari, Fatemeh Goldani and Seyed Mohammadreza Parizadeh
Affiliation:
- Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Gastric cancer, tissue mirna, Helicobacter pylori, normal flora, miRNA, gastric mucosa.
Abstract: Gastric cancer (GC) has a high mortality rate with a poor 5-year survival. Helicobacter pylori (H. pylori) is present as part of the normal flora of stomach. It is found in the gastric mucosa of more than half of the world population. This bacterium is involved in developing H. pylori-induced GC due to the regulation of different micro ribonucleic acid (miRNA or miR). miRNAs are small noncoding RNAs and are recognized as prognostic biomarkers for GC that may control gene expression. miRNAs may function as tumor suppressors, or oncogenes. In this review, we evaluated studies that investigated the ectopic expression of miRNAs in the prognosis of H. pylori positive and negative GC.
Export Options
About this article
Cite this article as:
Parizadeh Mostafa Seyed , Jafarzadeh-Esfehani Reza , Avan Amir *, Ghandehari Maryam , Goldani Fatemeh and Parizadeh Mohammadreza Seyed , The Prognostic and Predictive Value of microRNAs in Patients with H. pylori-positive Gastric Cancer, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/1381612825666190110144254
DOI https://dx.doi.org/10.2174/1381612825666190110144254 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Insights in Testing and Imaging Techniques for Solid Tumor Response Evaluation
Neuroscience and Biomedical Engineering (Discontinued) Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Editorial [Hot Topic: How Drugs may Work to Better Protect the Gastrointestinal Tract: Mechanisms Involved in Gastrointestinal Tract Protection]
Current Pharmaceutical Design The Complex Biology of FOXO
Current Drug Targets Editorial [Hot Topic: Benefits, Problems and Alternatives to COX-2 Inhibition (Guest Editor: Angel Lanas)]
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Intraorganellar Acidification by V-ATPases: A Target in Cell Proliferation and Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Anticancer Effects of Garlic and Garlic-derived Compounds for Breast Cancer Control
Anti-Cancer Agents in Medicinal Chemistry Engineered Nanoparticles in Cancer Therapy
Recent Patents on Drug Delivery & Formulation Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors
Current Genomics The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics
Current Pharmacogenomics Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Evolution of Resistance to Cancer Therapy
Current Pharmaceutical Design Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design